BuSpar Appeal: Bristol Argues Mylan Evaded Waxman/Hatch By Filing Suit

Mylan attempted to circumvent Waxman/Hatch procedures by filing suit against Bristol-Myers Squibb over its BuSpar (buspirone) metabolite patent before issuing a Paragraph IV certification, Bristol argued before the federal circuit appeals court in Washington D.C. July 12.